# Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion

Study · id `cardio:ct-nct07002476` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07002476](<https://clinicaltrials.gov/study/NCT07002476>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07002476

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 978 participants.

## Technical summary

Registry record NCT07002476. Randomized; single masking; primary purpose treatment. Start 2025-06-19 (actual); primary completion 2027-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 978 participants (planned count; ClinicalTrials.gov record NCT07002476, source copy `cardio:ctgov-nct07002476-2026-09-02`, retrieved 2026-10-26)
- Started: 2025-06-19 (actual) (ClinicalTrials.gov record NCT07002476, source copy `cardio:ctgov-nct07002476-2026-09-02`, retrieved 2026-10-26)
- Primary completion: 2027-03-01 (anticipated) (ClinicalTrials.gov record NCT07002476, source copy `cardio:ctgov-nct07002476-2026-09-02`, retrieved 2026-10-26)
- Completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07002476, source copy `cardio:ctgov-nct07002476-2026-09-02`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07002476, source copy `cardio:ctgov-nct07002476-2026-09-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07002476-2026-09-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
- Acronym: EAST-LDL
- Condition: Stroke
- Intervention (Drug): guideline-recommended SoC
- Intervention (Drug): Recaticimab (intensive)
- Lead sponsor: Shanghai East Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Shanghai East Hospital (`cardio:org-shanghai-east-hospital`)

## Provenance

Content hash: 392b3fb61e8fe197de2a426f39e3e987e89ec2fb59b54bcad2ea77b4a8b83516
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
